biostudies-literatureOza BAstraZeneca plcCancer Research UKMedical Research Council106482https://www.ebi.ac.uk/biostudies/studies/S-EPMC8520913biostudies-literatureUnknown108<h4>Background</h4>20-60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, radiotherapy, hormones and oral tyrosine-kinase inhibitors (TKIs), with limited success. The predominant global standard-of-care after nephrectomy remains active monitoring. Immune checkpoint inhibitors (ICIs) are effective in the treatment of metastatic RCC; RAMPART will investigate these agents in the adjuvant setting.<h4>Methods/design</h4>RAMPART is an international, UK-led trial investigating the addition of ICIs after nephrectomy in patients with resected locally advanced RCC. RAMPART is a multi-arm multi-stage (MAMS) platform trial, upon which additional researchContemporary clinical trialsRAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.PMC8520913MC_UU_00004/0928690MC_UU_00004/01Shakeshaft CBex AMcWhirter AOza BParmar MKBHarrison DFielding AScovell SMeade ANathan PMulhere SDavis IDRini BStewart GDKaplan RSmith BAlbiges LRitchie AChoueiri TKLarkin JEisen TFrangou EPowles TStockler MRThorogood NChoodari-Oskooei BBryant HfalseRAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.<h4>Background</h4>20-60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, radiotherapy, hormones and oral tyrosine-kinase inhibitors (TKIs), with limited success. The predominant global standard-of-care after nephrectomy remains active monitoring. Immune checkpoint inhibitors (ICIs) are effective in the treatment of metastatic RCC; RAMPART will investigate these agents in the adjuvant setting.<h4>Methods/design</h4>RAMPART is an international, UK-led trial investigating the addition of ICIs after nephrectomy in patients with resected locally advanced RCC. RAMPART is a multi-arm multi-stage (MAMS) platform trial, upon which additional research2021-01-01T00:00:00Z2021 Sep2025-04-05T12:56:21.227Z2025-04-05T12:56:21.227ZS-EPMC85209133453840210.1016/j.cct.2021.106482